Latest news with #DecisionDx-Melanoma
Yahoo
30-05-2025
- Business
- Yahoo
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025
Castle Biosciences, Inc. (NASDAQ:CSTL) has announced new data to be presented at ASCO 2025 showing that its DecisionDx-Melanoma test is linked to a 32% reduction in mortality risk for patients with cutaneous melanoma compared to those who were untested. The findings come from the largest real-world study of gene expression profile testing in melanoma, analyzing over 13,500 patients in collaboration with the National Cancer Institute's SEER Program Registries. A doctor using a microscope in a lab, conducting research on cancer treatments. Castle Biosciences, Inc. (NASDAQ:CSTL)'s Dx-Melanoma test, which evaluates a 31-gene expression profile, offers significant, independent risk stratification beyond traditional AJCC staging, helping clinicians make more precise, personalized treatment decisions. According to lead author Dr. Merve Hasanov, the test enables more accurate mortality risk predictions based on a patient's unique tumor biology, allowing for better-tailored care. These results further affirm the test's association with improved patient survival and its potential to guide risk-aligned management strategies. DecisionDx-Melanoma has been ordered more than 200,000 times and is supported by over 50 peer-reviewed studies, underscoring its growing role in melanoma care and its impact on patient outcomes. While we acknowledge the potential of CSTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CSTL and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
30-05-2025
- Health
- Business Upturn
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
By GlobeNewswire Published on May 30, 2025, 01:30 IST FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30-June 3, 2025, in Chicago. This includes the latest findings from Castle's ongoing collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (NCI's SEER) Program Registries affirming the significant, independent risk stratification provided by DecisionDx-Melanoma in an expanded, real-world cohort of more than 13,500 patients who received the test as part of their melanoma care. 'Management decisions for melanoma patients, such as referrals for sentinel lymph node biopsy and surveillance intensity, are guided by a patient's risk of dying from their disease,' said Merve Hasanov, M.D., oncologist and director of the division of medical oncology at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio. 'The findings being presented at ASCO demonstrate that the DecisionDx-Melanoma test can provide more precise mortality risk predictions based on a patient's unique tumor biology and can improve upon the population-based risk assessment provided by American Joint Committee on Cancer (AJCC) staging. This can, in turn, help clinicians tailor treatment approaches to individual patient needs.' Castle's presentations at ASCO will take place during the Melanoma/Skin Cancers poster session on Sunday, June 1, from 9 a.m. to 12 p.m. Central time in Hall A – Posters and Exhibits. Title: The 31-gene expression profile can guide better risk-aligned care decisions for patients with stage I–III cutaneous melanoma: an NCI-SEER analysis Abstract: 9573 Poster Bd #: 56 Lead Author: Merve Hasanov, M.D., oncologist and director of the division of medical oncology at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio Study highlights : This study presents an updated validation of the DecisionDx-Melanoma test's ability to independently stratify CM patients' mortality risk within AJCC sub-stages (stages I-IIA, IIB-C and III) as part of Castle's ongoing collaboration with the NCI's SEER Program Registries. In this large, real-world cohort of 13,560 patients with CM – the largest real-world study of gene expression profile testing to date – the test provided significant risk stratification within the AJCC sub-groups (p<0.001). In multivariable analysis that included key AJCC staging criteria (i.e., Breslow thickness, ulceration and nodal status) and other commonly used clinicopathologic risk factors (e.g., age and mitotic rate), DecisionDx-Melanoma test results emerged as a significant predictor of melanoma-specific mortality (Class 2B hazard ratio=4.59, p<0.001; Class 1B/2A hazard ratio=3.42, p<0.001). Further, testing with DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients, providing further evidence of the test's association with improved patient survival and affirming the test's potential to inform risk-aligned treatment pathway decisions that may lead to improved patient outcomes. 1 : This study presents an updated validation of the DecisionDx-Melanoma test's ability to independently stratify CM patients' mortality risk within AJCC sub-stages (stages I-IIA, IIB-C and III) as part of Castle's ongoing collaboration with the NCI's SEER Program Registries. In this large, real-world cohort of 13,560 patients with CM – the largest real-world study of gene expression profile testing to date – the test provided significant risk stratification within the AJCC sub-groups (p<0.001). In multivariable analysis that included key AJCC staging criteria (i.e., Breslow thickness, ulceration and nodal status) and other commonly used clinicopathologic risk factors (e.g., age and mitotic rate), DecisionDx-Melanoma test results emerged as a significant predictor of melanoma-specific mortality (Class 2B hazard ratio=4.59, p<0.001; Class 1B/2A hazard ratio=3.42, p<0.001). Further, testing with DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients, providing further evidence of the test's association with improved patient survival and affirming the test's potential to inform risk-aligned treatment pathway decisions that may lead to improved patient outcomes. Title: Independent validation of a 16-protein test to assess malignant potential of small uveal melanocytic tumors Abstract: 9590 Poster Bd #: 73 Lead Author and Presenter: David Alan Reichstein, M.D., retina specialist and ocular oncologist at Tennessee Retina, Nashville, Tennessee Study highlights: UM is a rare but aggressive eye cancer with up to 50% of patients developing metastatic disease. While tumor biopsy-based molecular testing (i.e., DecisionDx-UM) is widely utilized to identify high-risk biology, repeated intraocular tumor biopsies are not feasible for monitoring small uveal melanocytic tumors of indeterminate malignant potential (UMTIMP). This multicenter study explored a novel diagnostic approach designed to analyze protein biomarkers in aqueous humor (AH) obtained through minimally invasive, in-office liquid biopsy of the anterior chamber of the eye. In the independent validation, the 17-biomarker test that evaluates 16 proteins and tumor diameter information successfully distinguished between low- and high-risk UM lesions with a sensitivity of 91%, specificity of 50%, negative predictive value of 92% and positive predictive value of 47%. If developed, this high-sensitivity test could help to accurately identify high-risk melanocytic lesions that would merit more invasive intraocular biopsy and further prognostic testing with DecisionDx-UM, -PRAME and -UM Seq . The study findings support a liquid biopsy approach to monitor suspicious UMTIMPs for malignant transformation to inform more timely decision-making and earlier therapeutic interventions to help improve patient outcomes. The full abstracts outlined above can be found at the ASCO website here. For more information regarding Castle's data at ASCO, please visit booth # 24149. About DecisionDx-Melanoma DecisionDx-Melanoma is a 31-gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient's individual risk of sentinel lymph node (SLN) positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma's clinical value is supported by more than 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test's results. Through March 31, 2025, DecisionDx-Melanoma has been ordered more than 200,000 times for patients diagnosed with cutaneous melanoma. About DecisionDx-UM DecisionDx-UM is Castle Biosciences' 15-gene expression profile (GEP) test that uses an individual patient's tumor biology to predict individual risk of metastasis in patients with uveal melanoma (UM). DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the United States. Since 2009, the American Joint Committee on Cancer (AJCC; v7 and v8) Staging Manual for UM has specifically identified the GEP test as a prognostic factor that is recommended for collection as a part of clinical care. Further, the National Comprehensive Cancer Network (NCCN) guidelines for UM include the DecisionDx-UM test result as a prognostic method for determining risk of metastasis and recommended differential surveillance regimens based on a Class 1A, 1B and 2 result. DecisionDx-UM is currently the only prognostic test for UM that has been validated in prospective, multi-center studies, and it has been shown to be a superior predictor of metastasis compared to other prognostic factors, such as chromosome 3 status, mutational status, AJCC stage and cell type. It is estimated that nearly 8 in 10 patients diagnosed with UM in the United States receive the DecisionDx-UM test as part of their diagnostic workup. About Castle Biosciences Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the significant, independent risk stratification provided by DecisionDx-Melanoma; DecisionDx-Melanoma's ability to (i) provide more precise mortality risk predictions and improve upon population-based risk assessment provide by AJCC staging, (ii) be a significant predictor of melanoma-specific mortality and (iii) improve patient survival and lead to improved patient outcomes; and DecisionDx-UM's ability to help accurately identify high-risk melanocytic lesions and improve patient outcomes. The words 'believe,' 'can' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Report for the three months ended March 31, 2025 and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law. Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration. JCO Precis. Oncol . 2023; 7. doi: 10.1200/PO.23.00044 Investor Contact:Camilla Zuckero [email protected] Media Contact:Allison Marshall [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
21-05-2025
- Business
- Yahoo
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at A replay of the webcast will be available following the conclusion of the live broadcast. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at A replay of the webcast will be available following the conclusion of the live broadcast. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences Inc.
Yahoo
07-05-2025
- Health
- Yahoo
Castle Biosciences Celebrates Skin Cancer Awareness Month
Aaron Farberg, M.D., FAAD, double board-certified dermatologist, Mohs surgeon and chief medical officer of Bare Dermatology in Dallas, will lead the discussion, joined by dermatology interest group students Mitchell Hanson and Brianna Speigel. Topics will include navigating a diagnosis, emotional support resources, survivorship planning and how patients and caregivers can more effectively advocate for melanoma care. Registration details can be found here . Empowering Patients and Caregivers: IMPACT Melanoma Virtual Patient Symposium Castle is proud to continue its long-standing partnership with IMPACT Melanoma by sponsoring the organization's upcoming virtual patient symposium, 'Melanoma Diagnosis: A Toolkit to Support the Journey.' The event will be held on Wednesday, May 21, 2025, at 6 p.m. ET , and has been designed to provide individuals newly diagnosed with melanoma — and their support networks — with practical tools, resources and compassionate guidance to navigate the melanoma journey. 'At Castle, our mission is rooted in delivering clinically actionable information to patients and their clinical care teams — and that begins with awareness and education,' said Derek Maetzold, president and chief executive officer of Castle Biosciences. 'By supporting organizations like IMPACT Melanoma and sharing real patient stories like Leah's, we aim to drive conversations around early detection and personalized risk assessment in an effort to help improve patient outcomes.' FRIENDSWOOD, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is recognizing Skin Cancer Awareness Month this May by supporting a series of initiatives designed to raise awareness, educate patients and families and empower those impacted by skin cancer. Story Continues 'This symposium was created to meet people where they are — at a vulnerable moment in their lives,' said Deb Girard, executive director of IMPACT Melanoma. 'We want everyone who attends, whether they are just beginning their journey or supporting someone who is, to walk away feeling more informed, supported and empowered.' Leah's Story: Living Confidently with the Support of DecisionDx®-Melanoma Improving patient care is at the heart of Castle's mission. This month, Castle is sharing the powerful story of Leah Adams, a melanoma survivor who used Castle's DecisionDx-Melanoma test to better understand her predicted risk of recurrence. 'People don't understand how serious melanoma is,' said Adams. 'The DecisionDx-Melanoma test allows you to really see your risk of recurrence — whether it's high- or low-risk — so you can do everything possible to protect your largest organ. Having the reassurance of the low-risk result helps me move forward and be able to show up for my family and for myself.' Leah's full story can be viewed here. Walking Together Toward a Cure: Castle Rallies for Melanoma Awareness Across the Nation As part of its commitment to advancing skin cancer awareness, Castle is proud to continue its support of AIM at Melanoma and the Melanoma Research Foundation by participating in multiple advocacy walks throughout the month of May. Taking place across the country, these events bring together survivors, caregivers, clinicians and advocates to raise critical funds for research, education and outreach — united by a shared goal of finding a cure. Raising National Awareness: USA TODAY 2025 Skin Health Campaign Castle is also participating in the 2025 Skin Health Campaign by USA TODAY. The Company is collaborating on an article titled 'Transforming Skin Cancer and Melanoma Outcomes,' which will appear in the May 30 print edition of USA TODAY and in the digital campaign on and Future of Personal Health. The article features Shannon Trotter, D.O., FAAD, board-certified dermatologist and host of the Derm-it Trotter! Don't Swear About Skincare podcast, and melanoma advocate Leah Adams, and highlights the growing role of diagnostic testing in guiding personalized care decisions for individuals diagnosed with melanoma. More information about Castle's tests for patients with skin cancer can be found at About IMPACT Melanoma IMPACT Melanoma, a national non-profit 501(c)(3) organization, is the nation's leading non-profit dedicated to significantly reducing melanoma in the United States and saving lives. The focus is on prevention education programs that include customized and integrated programs for communities. In addition to skin cancer prevention education and programs, the organization is committed to supporting melanoma patients and their families and advocating for and influencing urban development policies to address shade equity in America. To learn more about IMPACT Melanoma, visit About AIM at Melanoma Founded in 2004, AIM at Melanoma is a global foundation dedicated to finding more effective treatments and, ultimately, the cure for melanoma. By directing and funding paradigm-shifting research initiatives — educating patients, healthcare professionals, and the public — and advocating for survivors and their families, AIM at Melanoma's goal is to end this disease in our lifetime while improving the lives of those it affects. AIM at Melanoma is dedicated to innovation in melanoma research, information and support, and legislation, policy and advocacy. For more information, visit About Melanoma Research Foundation The Melanoma Research Foundation (MRF) is a 501(c)(3) non-profit organization and the largest independent organization devoted to melanoma. Committed to the support of medical research to develop effective treatments and eventually a cure for melanoma, the MRF also educates patients and physicians about the prevention, diagnosis and treatment of cutaneous melanoma and the melanoma rare subtypes. The MRF is a dedicated advocate for the melanoma community, helping to raise awareness of this disease and the need for a cure. To learn more about the MRF, visit About DecisionDx-Melanoma DecisionDx-Melanoma is a 31-gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient's individual risk of sentinel lymph node (SLN) positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma's clinical value is supported by more than 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test's results. Through March 31, 2025, DecisionDx-Melanoma has been ordered more than 200,000 times for patients diagnosed with cutaneous melanoma. More information about the test and disease can be found at About Castle Biosciences Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. These forward-looking statements include, but are not limited to, statements concerning: Castle's ability to (i) raise awareness, educate patients and families and empower those impacted by skin cancer and (ii) deliver actionable information to patients and their clinical care teams; and DecisionDx-Melanoma's ability to (i) provide comprehensive, personalized results to guide risk-aligned management decisions for patients with stage I-III cutaneous melanoma and (ii) help clinicians make more informed, more precise treatment decisions. The words 'believe,' 'can,' 'could,' 'potential' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each filed or to be filed with the SEC, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law. Investor Contact: Camilla Zuckero czuckero@ Media Contact: Allison Marshall amarshall@ Source: Castle Biosciences Inc. A video accompanying this announcement is available at
